NDA 008975 · Ani Pharms
Purified Cortrophin Gel
Corticotropin · Injection · Adrenocorticotropic Hormone
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1954
Jun 16, 1954
Approved uses
1
Original approval plus efficacy supplements
Registered trials
176
26 Phase 3, 13 recruiting
FAERS reports
12
9 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 5, 2026.
INDICATIONS AND USAGE Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 16, 1954 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
- PURIFIED CORTROPHIN GEL · CORTICOTROPIN 40 UNITS/ML · INJECTABLE, INJECTION · Discontinued
- PURIFIED CORTROPHIN GEL · CORTICOTROPIN 80 UNITS/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Corticotropin" as an intervention, any sponsor and status, largest first.
- Current Status of Islet Alpha Cell Function in Patients with Type 2 DiabetesPivotal-lookingRecruiting
Nanjing First Hospital, Nanjing Medical UniversityAcademic, hospital or other
NCT06825182 · 1,000 participants (planned) · Start Nov 7, 2024 · Primary completion Aug 1, 2025
Drug: Outpatient newly diagnosed type 2 diabetes subjects; Inpatient newly diagnosed type 2 diabetes subjects · For: Type 2 Diabetes Mellitus
Sites: Nanjing, China
- Evaluation of GSK561679 in Women With Post-Traumatic Stress DisorderPivotal-lookingCompleted
Emory UniversityAcademic, hospital or other
NCT01018992 · 267 participants · Start Dec 2009 · Primary completion Aug 2014
Drug: GSK561679; Placebo · For: Stress Disorders, Post-Traumatic
Sites: San Francisco, California; Atlanta, Georgia; New York, New York · 4 sites in all
- Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid ArthritisPivotal-lookingCompleted
MallinckrodtIndustry
NCT02919761 · 259 participants · Start Nov 7, 2016 · Primary completion Oct 17, 2018
Drug: Acthar Gel; Placebo · For: Arthritis, Rheumatoid
Sites: San Leandro, California; Upland, California; Boynton Beach, Florida · 59 sites in all
University of MichiganAcademic, hospital or other
NCT01673087 · 256 participants · Start Oct 2012 · Primary completion Aug 15, 2017
Drug: Metyrapone; Dexamethasone and 2 more · For: Stress
Sites: Ann Arbor, Michigan
Haukeland University HospitalAcademic, hospital or other
NCT02818660 · 232 participants · Start May 21, 2016 · Primary completion Dec 21, 2017
Drug: Synachten · For: Adrenal Insufficiency
Sites: Bergen, Norway
- Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism(ADOPA)Pivotal-lookingCompleted
Chongqing Medical UniversityAcademic, hospital or other
NCT04461535 · 228 participants · Start Jul 8, 2020 · Primary completion Feb 20, 2023
Drug: Adrenocorticotropic hormone · For: Primary Aldosteronism
Sites: Chongqing, China
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07005154 · 218 participants (planned) · Start Aug 19, 2025 · Primary completion May 31, 2032
Drug: ASP5541; Prednisone and 3 more · For: Prostate Cancer; Metastatic Castration-Resistant Prostate Cancer; Metastatic Hormone Sensitive Prostate Cancer
Sites: Huntsville, Alabama; San Diego, California; Tampa, Florida · 54 sites in all
- CRF2 Agonist for the Treatment of Worsening Heart FailurePivotal-lookingRecruiting
Corteria PharmaceuticalsIndustry
NCT06815471 · 210 participants (planned) · Start Aug 7, 2025 · Primary completion Jul 2027
Drug: COR-1167; Placebo · For: Worsening Heart Failure
Sites: Indianapolis, Indiana; Detroit, Michigan; Greensboro, North Carolina · 55 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain3
- dizziness2
- fatigue2
- peripheral swelling2
- anxiety1
- arthralgia1
- back pain1
- blood glucose increased1
- blood potassium increased1
- blood pressure decreased1
- blood pressure increased1
- blood uric acid decreased1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
Auchus RJ, Hamidi O, Pivonello R, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Gout.
Underwood M · BMJ Clin Evid 2011 · Systematic Review
- Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.
Siefried KJ, Acheson LS, Lintzeris N, et al. · CNS Drugs 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.
Sarafoglou K, Kim MS, Lodish M, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M, Clemens PR, Perlman SJ, et al. · JAMA Neurol 2022 · Multicenter Study, Randomized Controlled Trial
- Dynamic Testing for Differential Diagnosis of ACTH-Dependent Cushing Syndrome: A Systematic Review and Meta-analysis.
Ceccato F, Barbot M, Mondin A, et al. · J Clin Endocrinol Metab 2023 · Meta-Analysis, Systematic Review
Sponsor: Ani Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.